Sugi Predict

Sugi Predict / Compounds / SCHEMBL7060490

SCHEMBL7060490

SCHEMBL7060490

CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 4/20 0.56
▸ CTSK P43235 3/20 0.56
▸ CTSB P07858 2/20 0.56
▸ CTSL P07711 1/20 0.56
▸ AKT1 P31749 1/20 0.54
▸ ACE P12821 2/20 0.54
▸ KLK5 Q9Y337 1/20 0.53
▸ EPHX2 P34913 1/20 0.52
▸ SCN9A Q15858 4/20 0.52
▸ ATM Q13315 1/20 0.49
▸ KMT2A Q03164 1/20 0.48
▸ APP P05067 1/20 0.48
▸ MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032021 1.00 CTSS (0.56) CTSSCTSKCTSBCTSLAKT1
SCHEMBL3171386 1.00 CTSS (0.56) CTSSCTSKCTSBCTSLAKT1
SCHEMBL29484191 0.96 CTSS (0.57) CTSSCTSKCTSBCTSLAKT1
SCHEMBL18206854 0.92 CTSS (0.50) CTSSCTSKCTSBCTSLAKT1
SCHEMBL18206856 0.92 CTSS (0.50) CTSSCTSKCTSBCTSLAKT1
SCHEMBL18206853 0.92 CTSS (0.50) CTSSCTSKCTSBCTSLAKT1
SCHEMBL22929153 0.91 BCL2 (0.56) CTSSCTSKCTSBCTSL
SCHEMBL19234621 0.90 PPARG (0.46) CTSSCTSKCTSBCTSLAKT1
SCHEMBL3750286 0.90 CTSS (0.55) CTSSCTSKCTSBCTSLAKT1
SCHEMBL10723853 0.90 CTSS (0.55) CTSSCTSKCTSBCTSLAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118620035-A Method for synthesizing bivalirudin by half recombinant expression 铭诚惠众(江苏)药物研究有限公司 2024-09-10 — — CN claimed
CN-116239651-A Liquid phase synthesis method of diclofenac 深圳翰宇药业股份有限公司 2023-06-09 — — CN claimed
CN-118620035-A Method for synthesizing bivalirudin by half recombinant expression 铭诚惠众(江苏)药物研究有限公司 2024-09-10 — — CN disclosed
CN-118620035-A Method for synthesizing bivalirudin by half recombinant expression 铭诚惠众(江苏)药物研究有限公司 2024-09-10 — — CN disclosed
CN-116239651-A Liquid phase synthesis method of diclofenac 深圳翰宇药业股份有限公司 2023-06-09 — — CN disclosed
CN-100413882-C Linear basic compounds having NK-2 antagonistic activity and formulations thereof MENARINI RICERCHE SPA (IT) 2008-08-27 — — CN disclosed
CN-1717396-A Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AG (DE) 2006-01-04 — — CN disclosed
CN-1578786-A Linear basic compounds having NK-2 antagonistic activity and formulations thereof MENARINI RICERCHE SPA (IT) 2005-02-09 — — CN disclosed
US-20030130272-A1 Anthracene derivatives as anti-cancer agents BTG INTERNATIONAL LIMITED (GB) 2003-07-10 — — US disclosed
EP-1244624-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2002-10-02 — — EP disclosed
WO-2001044190-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2001-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130272-A1 Anthracene derivatives as anti-cancer agents TOP2B, TOP1, TOP2A CTSS 2690/4885CTSK 2190/4885CTSB 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.